pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

bioaxone-biosciences PRESS RELEASE ARCHIVE

Jun 22, 2022

BioAxone BioSciences Announces Patent Issued for Pharmaceutical Compositions of BA-210, a Rho Inhibitor for the Treatment of Spinal Cord Injury

Jun 21, 2021

BioAxone BioSciences Announces License of Cerebral Cavernous Malformations Drug Candidate BA-1049 and Portfolio of Rho Kinase Inhibitors to Neurelis

Jun 8, 2021

BioAxone BioSciences Announces Notice of Allowance for Self-Delivering RNA Interference for the Treatment of Spinal Cord Injury

Aug 28, 2020

BioAxone BioSciences Announces Notice of Allowance that Expands Scope of Key ROCK Inhibitors for Treatment of Cerebral Aneurysms

Dec 16, 2019

CORRECTING and REPLACING BioAxone BioSciences Expands Patent for Treatment of Cerebral Cavernous Malformations and Cerebral Aneurysms with Rho Kinase Inhibitors

Sep 12, 2019

BioAxone BioSciences Announces Publication in Translational Stroke Research of Cavernous Angioma Disease Research Article

Sep 27, 2018

BioAxone BioSciences Awarded Fast-Track SBIR Grant for Continued Development of Rho Kinase 2 Inhibitor

Aug 15, 2018

BioAxone BioSciences’ Scientific Advisory Board Member, Mark Bear, PhD, Receives $500,000 Beckman-Argyros Vision Research Award

Aug 8, 2018

BioAxone BioSciences Receives Notice of Allowance on Patent for Treatment of Cerebral Cavernous Malformations and Cerebral Aneurysms with Rho Kinase Inhibitors

Aug 1, 2018

BioAxone BioSciences CEO Lisa McKerracher Speaker at NeuroTrauma2018 Conference

Jul 10, 2018

BioAxone BioSciences Receives Notice of Allowance for Composition of Matter Patent Covering Novel ROCK2 Inhibitor

Jun 28, 2018

BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding for Continued Development of sd-rxRNA Drug Candidate for the Treatment of Spinal Cord Injury

Jun 28, 2018

BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding for Continued Development of sd-rxRNA Drug Candidate for the Treatment of Spinal Cord Injury

Apr 10, 2018

BioAxone BioSciences Appoints Ronald S. Goldstein as CFO

Aug 10, 2017

BioAxone BioSciences CEO Lisa McKerracher Accepts Role of Consortium Advisory Panelist for the Christopher Reeve Foundation

Aug 2, 2017

BioAxone BioSciences Receives Notice of Award for NIH/SBIR Funding of IND-Enabling Studies to Continue Development of BA-1049 to Treat Cerebral Cavernous Malformations

Jul 19, 2017

BioAxone BioSciences Announces Peer-Reviewed Research Article on Axon Regeneration Published in Frontiers Journal Series

May 23, 2017

BioAxone BioSciences CEO Lisa McKerracher Invited Speaker at the 12th Annual Neurotech Investing and Partnering Conference, Orphan Disease Panel

May 11, 2017

BioAxone BioSciences Announces New Hires to Support Investigational New Drug Filing

May 2, 2017

BioAxone BioSciences Continues Plans for Growth with Manufacturing Contract

Apr 20, 2017

BioAxone BioSciences Appoints Dr. Catherine Sohn to Lead Corporate Development

Sep 24, 2013

Nordion and BioAxone BioSciences Reach an Agreement to Settle Claims

Google Analytics Alternative